High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

PURPOSE: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Cortes, Jorge E., Kantarjian, Hagop M., Goldberg, Stuart L., Powell, Bayard L., Giles, Francis J., Wetzler, Meir, Akard, Luke, Burke, John M., Kerr, Robert, Saleh, Mansoor, Salvado, August, McDougall, Karen, Albitar, Maher, Radich, Jerald
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979200/
https://ncbi.nlm.nih.gov/pubmed/19720924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.3869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados